MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciag270

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026

Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi.

Feser Mary, Maphosa Thulani, Shroufi Amir, Rangaraj Ajay, Talbot Virginia R, Songane Mario, Qian Yiqi, Matiya Eddie, Lawrence David S, Arena Caroline, Srinivasan Anjali, Nyirenda-Dziwani Eltas, Ford Nathan, Nyirenda Rose, Phillips Andrew, Freedberg Kenneth A, Tiam Appolinaire, Jarvis Joseph N, Hyle Emily P

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Cryptococcal meningitis (CM) causes 13%-20% of deaths among people with HIV (PWH) globally. We examined the cost-effectiveness of improving access to CM diagnostics and treatment among PWH initiating HIV care with a positive serum cryptococcal antigen (CrAg) test in Malawi.

METHODS

We used the CEPAC-I model to simulate (1) Current care (CM treatment if diagnosed with CM; otherwise preemptive fluconazole) and assessed 7 intervention strategies to expand care: (2) lumbar puncture (LP); (3) semi-quantitative serum CrAg (CrAgSQ) alone; or (4) CrAgSQ plus confirmatory LP for asymptomatic people with CrAg+; and (5) 98% access to liposomal amphotericin B/flucytosine/fluconazole (LAmB/5FC/Fluc) for diagnosed CM, as well as improving access to CM treatment with each diagnostic strategy (6, 7, 8). The simulated cohort has mean CD4 27/µL, age 37 years; 16% have symptomatic CM, 28% asymptomatic CM, and 56% asymptomatic cryptococcemia. Model outcomes include 1-year survival, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) assessed at 2 cost-effectiveness thresholds: US$150/QALY and US$600/QALY.

RESULTS

Current care results in 70% 1-year survival, 10.67 QALYs, and costs US$2290/person. 98% access to LAmB/5FC/Fluc increases survival (+2.2%) and QALYs (+0.33 undiscounted QALYs) at lifetime costs of US$2320/person (ICER, US$140/QALY). CrAgSQ plus confirmatory LP for asymptomatic CrAg+ and 98% access to LAmB/5FC/Fluc results in +6.0% 1-year survival, +0.97 QALYs, +US$190/person (ICER, US$380/QALY). Results are sensitive to test characteristics and uptake.

INTERPRETATION: Improving access to LAmB/5FC/Fluc and expanding diagnostics to improve detection of asymptomatic CM would improve clinical outcomes and be cost-effective in Malawi and similar settings.

Для цитирования: Feser Mary, Maphosa Thulani, Shroufi Amir, Rangaraj Ajay, Talbot Virginia R, Songane Mario, Qian Yiqi, Matiya Eddie, Lawrence David S, Arena Caroline, Srinivasan Anjali, Nyirenda-Dziwani Eltas, Ford Nathan, Nyirenda Rose, Phillips Andrew, Freedberg Kenneth A, Tiam Appolinaire, Jarvis Joseph N, Hyle Emily P. Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2026. DOI: 10.1093/cid/ciag270.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.